The use of targeted isozyme-selective PAD inhibitors in synergy with other EMV modulators—aimed at either exosomes, MVs, or both populations in conjunction—present promising combinatory therapies for both cancers and neurodegenerative diseases. This evidence concerns the gene PADI4 and neurodegenerative disease.